Humana’s Medicare Advantage policy, effective January 1, 2024, does not cover peripheral nerve stimulators (PNS) for treating chronic pain. This is inconsistent with Medicare Fee-For-Service, Medicare Parts A and B, National Coverage Determinations, and Local Coverage Determinations, which all cover these PNS for certain patients. PNS has proven to be an effective treatment for many chronic pain conditions in hundreds of clinical studies, and in data showing PNS services were utilized by Medicare patients over 46,000 times between 2018-2022. This month, AAPM&R joined the Multi-specialty Pain Workgroup in urging Humana to revise its policy to align with Medicare’s coverage and ensure equitable access for its beneficiaries. If you have any comments or concerns, please contact healthpolicy@aapmr.org.